<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22441644</article-id><article-id pub-id-type="pmc">3341863</article-id><article-id pub-id-type="pii">bjc201289</article-id><article-id pub-id-type="doi">10.1038/bjc.2012.89</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis</article-title><alt-title alt-title-type="running">Everolimus in VEGFr-TKI-intolerant patients with mRCC</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bracarda</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hutson</surname><given-names>T E</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Porta</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Figlin</surname><given-names>R A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Calvo</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Grünwald</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Motzer</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Anak</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Panneerselvam</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><aff id="aff1"><label>1</label><institution>Ospedale San Donato USL8, Istituto Toscano Tumori (ITT)</institution>, Via Pietro Nenni, 20 52100 Arezzo, <country>Italy</country></aff><aff id="aff2"><label>2</label><institution>US Oncology/Baylor–Sammons Cancer Center</institution>, 3535 Worth Street, Dallas, TX 75246, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>IRCCS San Matteo University Hospital Foundation</institution>, Piazzale C. Golgi 19, Pavia I-27100, <country>Italy</country></aff><aff id="aff4"><label>4</label><institution>Samuel Oschin Comprehensive Cancer Institute, Cedars–Sinai Medical Center</institution>, 8700 Beverly Boulevard, AC 1085 North Tower, Los Angeles, CA 90048, <country>USA</country></aff><aff id="aff5"><label>5</label><institution>START Madrid, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro</institution>, 28050 Madrid, <country>Spain</country></aff><aff id="aff6"><label>6</label><institution>Medical School Hannover</institution>, Carl Neuberg Street 1, D-30627 Hannover, <country>Germany</country></aff><aff id="aff7"><label>7</label><institution>Hôpital Saint André CHU, 1 rue Jean Burguet</institution>, 33075 Bordeaux, <country>France</country></aff><aff id="aff8"><label>8</label><institution>Memorial Sloan–Kettering Cancer Center</institution>, 1275 York Avenue, New York, NY 10021, <country>USA</country></aff><aff id="aff9"><label>9</label><institution>Novartis Oncology Global Medical Affairs, One Health Plaza</institution>, East Hanover, NJ 07936, <country>USA</country></aff><aff id="aff10"><label>10</label><institution>Novartis Oncology Global Development</institution>, CH-4002 Basel, <country>Switzerland</country></aff><aff id="aff11"><label>11</label><institution>Novartis Oncology Biometrics and Data Management</institution>, 180 Park Avenue, Florham Park, NJ 07936, <country>USA</country></aff><aff id="aff12"><label>12</label><institution>Institut Gustave Roussy</institution>, 114 rue Edouard Vaillant, 94805 Villejuif, <country>France</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>sergio.bracarda@usl8.toscana.it</email></corresp></author-notes><pub-date pub-type="ppub"><day>24</day><month>04</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>22</day><month>03</month><year>2012</year></pub-date><volume>106</volume><issue>9</issue><fpage>1475</fpage><lpage>1480</lpage><history><date date-type="received"><day>31</day><month>10</month><year>2011</year></date><date date-type="rev-recd"><day>17</day><month>02</month><year>2012</year></date><date date-type="accepted"><day>22</day><month>02</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2012 Cancer Research UK</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title><offsets xml_i="6250" xml_f="6261" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="6272" xml_f="6698" txt_i="23" txt_f="449">A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and efficacy of everolimus in patients enrolled in the phase-III RECORD-1 trial who discontinued previous VEGFr-TKI therapy because of toxicity.</offsets></p></sec><sec><title><offsets xml_i="6720" xml_f="6728" txt_i="451" txt_f="459">Methods:</offsets></title><p><offsets xml_i="6739" xml_f="7087" txt_i="460" txt_f="808">Patients with an adverse event (AE) as their primary reason for discontinuation of previous VEGFr-TKI therapy were included. Median progression-free survival (PFS) for VEGFr-TKI-intolerant patients in each arm was estimated using the Kaplan–Meier method, and effect on PFS (hazard ratio (HR)) was calculated using the Cox proportional hazard model.</offsets></p></sec><sec><title><offsets xml_i="7109" xml_f="7117" txt_i="810" txt_f="818">Results:</offsets></title><p><offsets xml_i="7128" xml_f="7162" txt_i="819" txt_f="853">In VEGFr-TKI-intolerant patients (</offsets><italic><offsets xml_i="7170" xml_f="7171" txt_i="853" txt_f="854">n</offsets></italic><offsets xml_i="7180" xml_f="7272" txt_i="854" txt_f="946">=58, 14%), median PFS was 5.4 months with everolimus and 1.9 months with placebo (HR: 0.32; </offsets><italic><offsets xml_i="7280" xml_f="7281" txt_i="946" txt_f="947">P</offsets></italic><offsets xml_i="7290" xml_f="7333" txt_i="947" txt_f="990">=0.004). In sunitinib-intolerant patients (</offsets><italic><offsets xml_i="7341" xml_f="7342" txt_i="990" txt_f="991">n</offsets></italic><offsets xml_i="7351" xml_f="7438" txt_i="991" txt_f="1078">=26), median PFS was 5.1 months with everolimus and 2.8 months with placebo (HR: 0.28; </offsets><italic><offsets xml_i="7446" xml_f="7447" txt_i="1078" txt_f="1079">P</offsets></italic><offsets xml_i="7456" xml_f="7703" txt_i="1079" txt_f="1326">=0.033). Grade 3/4 AEs reported with everolimus in VEGFr-TKI-intolerant patients included infections (16%), fatigue (7%) and stomatitis (4%). The toxicity profile of everolimus was similar in the VEGFr-TKI-intolerant and overall study populations.</offsets></p></sec><sec><title><offsets xml_i="7725" xml_f="7736" txt_i="1328" txt_f="1339">Conclusion:</offsets></title><p><offsets xml_i="7747" xml_f="7863" txt_i="1340" txt_f="1456">Everolimus is well tolerated and efficacious with no increased toxicity in patients intolerant to VEGFr-TKI therapy.</offsets></p></sec></abstract><kwd-group><kwd>intolerance</kwd><kwd>kidney cancer</kwd><kwd>mTOR inhibitor</kwd><kwd>RAD001</kwd><kwd>VEGF-targeted therapy</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="8059" xml_f="8194" txt_i="1465" txt_f="1600">Sequential treatment with targeted therapies is the current standard of care for patients with metastatic renal cell carcinoma (mRCC) (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="8227" xml_f="8237" txt_i="1600" txt_f="1610">de Reijke </offsets><italic><offsets xml_i="8245" xml_f="8250" txt_i="1610" txt_f="1615">et al</offsets></italic><offsets xml_i="8259" xml_f="8265" txt_i="1615" txt_f="1621">, 2009</offsets></xref><offsets xml_i="8272" xml_f="8274" txt_i="1621" txt_f="1623">; </offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="8307" xml_f="8332" txt_i="1623" txt_f="1648">Escudier and Kataja, 2010</offsets></xref><offsets xml_i="8339" xml_f="8341" txt_i="1648" txt_f="1650">; </offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="8375" xml_f="8385" txt_i="1650" txt_f="1660">Ljungberg </offsets><italic><offsets xml_i="8393" xml_f="8398" txt_i="1660" txt_f="1665">et al</offsets></italic><offsets xml_i="8407" xml_f="8413" txt_i="1665" txt_f="1671">, 2010</offsets></xref><offsets xml_i="8420" xml_f="8422" txt_i="1671" txt_f="1673">; </offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="8456" xml_f="8499" txt_i="1673" txt_f="1716">National Comprehensive Cancer Network, 2012</offsets></xref><offsets xml_i="8506" xml_f="8837" txt_i="1716" txt_f="2047">). Targeted therapies approved for use in patients with mRCC include the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab, the VEGF receptor-tyrosine kinase inhibitors (VEGFr-TKIs) sorafenib, sunitinib and pazopanib, and the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus.</offsets></p><p><offsets xml_i="8844" xml_f="9201" txt_i="2048" txt_f="2405">First-line systemic treatment options supported by the highest level of clinical evidence for patients with mRCC are the VEGF-targeted agents sunitinib, pazopanib and bevacizumab (plus interferon-α) for patients of good or intermediate Memorial Sloan–Kettering Cancer Center (MSKCC) risk and the mTOR inhibitor temsirolimus for patients of poor MSKCC risk (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="9234" xml_f="9244" txt_i="2405" txt_f="2415">de Reijke </offsets><italic><offsets xml_i="9252" xml_f="9257" txt_i="2415" txt_f="2420">et al</offsets></italic><offsets xml_i="9266" xml_f="9272" txt_i="2420" txt_f="2426">, 2009</offsets></xref><offsets xml_i="9279" xml_f="9281" txt_i="2426" txt_f="2428">; </offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="9314" xml_f="9339" txt_i="2428" txt_f="2453">Escudier and Kataja, 2010</offsets></xref><offsets xml_i="9346" xml_f="9348" txt_i="2453" txt_f="2455">; </offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="9382" xml_f="9392" txt_i="2455" txt_f="2465">Ljungberg </offsets><italic><offsets xml_i="9400" xml_f="9405" txt_i="2465" txt_f="2470">et al</offsets></italic><offsets xml_i="9414" xml_f="9420" txt_i="2470" txt_f="2476">, 2010</offsets></xref><offsets xml_i="9427" xml_f="9429" txt_i="2476" txt_f="2478">; </offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="9463" xml_f="9506" txt_i="2478" txt_f="2521">National Comprehensive Cancer Network, 2012</offsets></xref><offsets xml_i="9513" xml_f="9788" txt_i="2521" txt_f="2796">). Although many patients obtain significant clinical benefit in terms of progression-free survival (PFS) from treatment with VEGF-targeted therapies, these agents are not well tolerated by all patients, leading to treatment discontinuation in a relevant percentage of cases.</offsets></p><p><offsets xml_i="9795" xml_f="10048" txt_i="2797" txt_f="3050">Adverse events (AEs) commonly observed in patients treated with VEGFr-TKIs include hypertension, hand-foot skin reaction (palmoplantar erythrodysesthesia), rash/desquamation, alopecia, diarrhoea, fatigue, hyponatremia, neutropenia and thrombocytopenia (</offsets><xref ref-type="bibr" rid="bib20"><offsets xml_i="10082" xml_f="10094" txt_i="3050" txt_f="3062">Ravaud, 2011</offsets></xref><offsets xml_i="10101" xml_f="10310" txt_i="3062" txt_f="3271">). The onset of treatment-related AEs may necessitate dose interruptions, dose adjustments and/or treatment discontinuation in some patients. In a phase-III trial of patients with mRCC treated with sunitinib (</offsets><italic><offsets xml_i="10318" xml_f="10319" txt_i="3271" txt_f="3272">n</offsets></italic><offsets xml_i="10328" xml_f="10351" txt_i="3272" txt_f="3295">=375) or interferon-α (</offsets><italic><offsets xml_i="10359" xml_f="10360" txt_i="3295" txt_f="3296">n</offsets></italic><offsets xml_i="10369" xml_f="10453" txt_i="3296" txt_f="3380">=375), 8% and 13% of patients, respectively, discontinued treatment because of AEs (</offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="10487" xml_f="10494" txt_i="3380" txt_f="3387">Motzer </offsets><italic><offsets xml_i="10502" xml_f="10507" txt_i="3387" txt_f="3392">et al</offsets></italic><offsets xml_i="10516" xml_f="10522" txt_i="3392" txt_f="3398">, 2007</offsets></xref><offsets xml_i="10529" xml_f="10605" txt_i="3398" txt_f="3474">). In the phase-III TARGET trial of patients with mRCC receiving sorafenib (</offsets><italic><offsets xml_i="10613" xml_f="10614" txt_i="3474" txt_f="3475">n</offsets></italic><offsets xml_i="10623" xml_f="10641" txt_i="3475" txt_f="3493">=451) or placebo (</offsets><italic><offsets xml_i="10649" xml_f="10650" txt_i="3493" txt_f="3494">n</offsets></italic><offsets xml_i="10659" xml_f="10865" txt_i="3494" txt_f="3700">=452), 21% of sorafenib-treated patients required dose interruptions primarily because of the occurrence of hand-foot skin reaction, whereas 6% of patients in the placebo group required dose interruptions (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="10898" xml_f="10907" txt_i="3700" txt_f="3709">Escudier </offsets><italic><offsets xml_i="10915" xml_f="10920" txt_i="3709" txt_f="3714">et al</offsets></italic><offsets xml_i="10929" xml_f="10935" txt_i="3714" txt_f="3720">, 2007</offsets></xref><offsets xml_i="10942" xml_f="11012" txt_i="3720" txt_f="3790">). In a phase-III study of patients with mRCC who received pazopanib (</offsets><italic><offsets xml_i="11020" xml_f="11021" txt_i="3790" txt_f="3791">n</offsets></italic><offsets xml_i="11030" xml_f="11048" txt_i="3791" txt_f="3809">=290) or placebo (</offsets><italic><offsets xml_i="11056" xml_f="11057" txt_i="3809" txt_f="3810">n</offsets></italic><offsets xml_i="11066" xml_f="11150" txt_i="3810" txt_f="3894">=145), 14% and 3% of patients, respectively, discontinued treatment because of AEs (</offsets><xref ref-type="bibr" rid="bib23"><offsets xml_i="11184" xml_f="11194" txt_i="3894" txt_f="3904">Sternberg </offsets><italic><offsets xml_i="11202" xml_f="11207" txt_i="3904" txt_f="3909">et al</offsets></italic><offsets xml_i="11216" xml_f="11222" txt_i="3909" txt_f="3915">, 2010</offsets></xref><offsets xml_i="11229" xml_f="11357" txt_i="3915" txt_f="4043">). Tolerability of first-line VEGFr-TKIs may be an even more relevant issue in clinical practice compared with clinical trials (</offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="11390" xml_f="11399" txt_i="4043" txt_f="4052">Choueiri </offsets><italic><offsets xml_i="11407" xml_f="11412" txt_i="4052" txt_f="4057">et al</offsets></italic><offsets xml_i="11421" xml_f="11427" txt_i="4057" txt_f="4063">, 2010</offsets></xref><offsets xml_i="11434" xml_f="11436" txt_i="4063" txt_f="4065">; </offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="11470" xml_f="11476" txt_i="4065" txt_f="4071">Porta </offsets><italic><offsets xml_i="11484" xml_f="11489" txt_i="4071" txt_f="4076">et al</offsets></italic><offsets xml_i="11498" xml_f="11505" txt_i="4076" txt_f="4083">, 2011b</offsets></xref><offsets xml_i="11512" xml_f="11611" txt_i="4083" txt_f="4182">). Results of two retrospective chart reviews from tertiary oncology centres in the United States (</offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="11644" xml_f="11653" txt_i="4182" txt_f="4191">Choueiri </offsets><italic><offsets xml_i="11661" xml_f="11666" txt_i="4191" txt_f="4196">et al</offsets></italic><offsets xml_i="11675" xml_f="11681" txt_i="4196" txt_f="4202">, 2010</offsets></xref><offsets xml_i="11688" xml_f="11701" txt_i="4202" txt_f="4215">) and Italy (</offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="11735" xml_f="11741" txt_i="4215" txt_f="4221">Porta </offsets><italic><offsets xml_i="11749" xml_f="11754" txt_i="4221" txt_f="4226">et al</offsets></italic><offsets xml_i="11763" xml_f="11770" txt_i="4226" txt_f="4233">, 2011b</offsets></xref><offsets xml_i="11777" xml_f="12007" txt_i="4233" txt_f="4463">) found that 26–37% of patients treated with first-line sunitinib or sorafenib required dose reductions because of AEs, 19–32% of patients required dose interruptions because of AEs and 5–18% discontinued treatment because of AEs.</offsets></p><p><offsets xml_i="12014" xml_f="12403" txt_i="4464" txt_f="4853">For patients who are intolerant to first-line VEGF-targeted therapy (i.e., discontinue therapy because of unacceptable toxicity), careful selection of second-line treatment is particularly critical in order to achieve maximum clinical benefit while minimising the occurrence of further treatment-related AEs. VEGF-targeted agents and mTOR inhibitors have distinct class effect toxicities (</offsets><xref ref-type="bibr" rid="bib20"><offsets xml_i="12437" xml_f="12449" txt_i="4853" txt_f="4865">Ravaud, 2011</offsets></xref><offsets xml_i="12456" xml_f="12886" txt_i="4865" txt_f="5295">); thus, patients who are intolerant to first-line VEGF-targeted therapy may be less likely to experience significant toxicity with a second-line mTOR inhibitor than a second-line VEGF-targeted agent. The phase-III RECORD-1 study evaluated the efficacy of the oral mTOR inhibitor everolimus in patients with mRCC whose disease had progressed on, or who were intolerant to, previous VEGFr-TKI therapy (sunitinib and/or sorafenib) (</offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="12920" xml_f="12927" txt_i="5295" txt_f="5302">Motzer </offsets><italic><offsets xml_i="12935" xml_f="12940" txt_i="5302" txt_f="5307">et al</offsets></italic><offsets xml_i="12949" xml_f="12955" txt_i="5307" txt_f="5313">, 2008</offsets></xref><offsets xml_i="12962" xml_f="12964" txt_i="5313" txt_f="5315">, </offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="12998" xml_f="13002" txt_i="5315" txt_f="5319">2010</offsets></xref><offsets xml_i="13009" xml_f="13166" txt_i="5319" txt_f="5476">). Median PFS was prolonged from 1.9 months (95% CI: 1.8–1.9) to 4.9 months (95% CI: 4.0–5.5) for patients who received placebo or everolimus, respectively (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="13200" xml_f="13207" txt_i="5476" txt_f="5483">Motzer </offsets><italic><offsets xml_i="13215" xml_f="13220" txt_i="5483" txt_f="5488">et al</offsets></italic><offsets xml_i="13229" xml_f="13235" txt_i="5488" txt_f="5494">, 2010</offsets></xref><offsets xml_i="13242" xml_f="13400" txt_i="5494" txt_f="5652">). Risk of disease progression was reduced by 67% for patients in the everolimus group, compared with patients in the placebo group (hazard ratio (HR): 0.33; </offsets><italic><offsets xml_i="13408" xml_f="13409" txt_i="5652" txt_f="5653">P</offsets></italic><offsets xml_i="13418" xml_f="13604" txt_i="5653" txt_f="5836"> &lt; 0.001). Based on these results, current clinical practice guidelines recommend everolimus as the standard of care for patients with mRCC who have failed initial VEGFr-TKI therapy (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="13637" xml_f="13647" txt_i="5836" txt_f="5846">de Reijke </offsets><italic><offsets xml_i="13655" xml_f="13660" txt_i="5846" txt_f="5851">et al</offsets></italic><offsets xml_i="13669" xml_f="13675" txt_i="5851" txt_f="5857">, 2009</offsets></xref><offsets xml_i="13682" xml_f="13684" txt_i="5857" txt_f="5859">; </offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="13717" xml_f="13742" txt_i="5859" txt_f="5884">Escudier and Kataja, 2010</offsets></xref><offsets xml_i="13749" xml_f="13751" txt_i="5884" txt_f="5886">; </offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="13785" xml_f="13795" txt_i="5886" txt_f="5896">Ljungberg </offsets><italic><offsets xml_i="13803" xml_f="13808" txt_i="5896" txt_f="5901">et al</offsets></italic><offsets xml_i="13817" xml_f="13823" txt_i="5901" txt_f="5907">, 2010</offsets></xref><offsets xml_i="13830" xml_f="13832" txt_i="5907" txt_f="5909">; </offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="13866" xml_f="13909" txt_i="5909" txt_f="5952">National Comprehensive Cancer Network, 2012</offsets></xref><offsets xml_i="13916" xml_f="13918" txt_i="5952" txt_f="5954">).</offsets></p><p><offsets xml_i="13925" xml_f="14140" txt_i="5955" txt_f="6170">Herein we present the results of a retrospective analysis of RECORD-1 that evaluated the efficacy and safety of everolimus in the subgroup of patients who discontinued previous VEGFr-TKI therapy because of toxicity.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="14185" xml_f="14206" txt_i="6171" txt_f="6192">Materials and methods</offsets></title><sec><title><offsets xml_i="14226" xml_f="14244" txt_i="6193" txt_f="6211">Patient population</offsets></title><p><offsets xml_i="14255" xml_f="14388" txt_i="6212" txt_f="6345">The study design of RECORD-1, an international, multicentre, double-blind, randomised phase-III trial, has been previously reported (</offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="14422" xml_f="14429" txt_i="6345" txt_f="6352">Motzer </offsets><italic><offsets xml_i="14437" xml_f="14442" txt_i="6352" txt_f="6357">et al</offsets></italic><offsets xml_i="14451" xml_f="14457" txt_i="6357" txt_f="6363">, 2008</offsets></xref><offsets xml_i="14464" xml_f="14557" txt_i="6363" txt_f="6456">). Adult patients (aged ⩾18 years) with measurable clear cell mRCC (according to RECIST 1.0 (</offsets><xref ref-type="bibr" rid="bib24"><offsets xml_i="14591" xml_f="14600" txt_i="6456" txt_f="6465">Therasse </offsets><italic><offsets xml_i="14608" xml_f="14613" txt_i="6465" txt_f="6470">et al</offsets></italic><offsets xml_i="14622" xml_f="14628" txt_i="6470" txt_f="6476">, 2000</offsets></xref><offsets xml_i="14635" xml_f="15388" txt_i="6476" txt_f="7229">)), which had progressed within 6 months of stopping treatment with sunitinib, sorafenib or both were included in the study. Previous treatment with bevacizumab, interleukin 2 or interferon-α also was permitted. Other key inclusion criteria were a Karnofsky performance status of at least 70% (scale 0–100, higher scores indicated better performance) and adequate bone marrow, hepatic and renal function. Patients in all MSKCC-risk categories (favourable, intermediate and poor) were included. Key exclusion criteria were previous treatment with temsirolimus, untreated central nervous system metastases and uncontrolled medical conditions (e.g., unstable angina pectoris, symptomatic congestive heart failure, recent myocardial infarction or diabetes).</offsets></p></sec><sec><title><offsets xml_i="15410" xml_f="15426" txt_i="7231" txt_f="7247">Study treatments</offsets></title><p><offsets xml_i="15437" xml_f="15674" txt_i="7248" txt_f="7485">Patients were stratified according to whether they received one or two previous VEGFr-TKIs and by MSKCC-risk group. Patients were then randomly assigned 2 : 1 to receive either continuous treatment with oral everolimus 10 mg once daily (</offsets><italic><offsets xml_i="15682" xml_f="15683" txt_i="7485" txt_f="7486">n</offsets></italic><offsets xml_i="15692" xml_f="15710" txt_i="7486" txt_f="7504">=277) or placebo (</offsets><italic><offsets xml_i="15718" xml_f="15719" txt_i="7504" txt_f="7505">n</offsets></italic><offsets xml_i="15728" xml_f="15782" txt_i="7505" txt_f="7559">=139), both in conjunction with best supportive care (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="15816" xml_f="15823" txt_i="7559" txt_f="7566">Motzer </offsets><italic><offsets xml_i="15831" xml_f="15836" txt_i="7566" txt_f="7571">et al</offsets></italic><offsets xml_i="15845" xml_f="15851" txt_i="7571" txt_f="7577">, 2010</offsets></xref><offsets xml_i="15858" xml_f="16328" txt_i="7577" txt_f="8047">). A cycle was 28 days of treatment. Doses were delayed or reduced (to 5 mg once daily) if patients had clinically significant haematological or other AEs that were considered by the investigator to be related to everolimus. Treatment continued until disease progression, unacceptable toxicity, death or discontinuation for any other reason. Patients randomly assigned to placebo who experienced disease progression were permitted to cross over to open-label everolimus.</offsets></p></sec><sec><title><offsets xml_i="16350" xml_f="16361" txt_i="8049" txt_f="8060">Assessments</offsets></title><p><offsets xml_i="16372" xml_f="17021" txt_i="8061" txt_f="8710">The primary reason for discontinuation of each previous anti-neoplastic therapy (AE, disease progression or other) was collected for all patients. Patients for whom an AE was the primary reason for discontinuation of previous sunitinib therapy, sorafenib therapy or both (i.e., discontinuation of previous VEGFr-TKI therapy because of unacceptable toxicity) were included in this subgroup analysis and assessed for PFS and safety. PFS was defined as the time from randomisation to the first documentation of disease progression or death from any cause and was documented according to RECIST 1.0 and assessed via blinded, independent central review (</offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="17055" xml_f="17062" txt_i="8710" txt_f="8717">Motzer </offsets><italic><offsets xml_i="17070" xml_f="17075" txt_i="8717" txt_f="8722">et al</offsets></italic><offsets xml_i="17084" xml_f="17090" txt_i="8722" txt_f="8728">, 2008</offsets></xref><offsets xml_i="17097" xml_f="17214" txt_i="8728" txt_f="8845">). Tumour measurements were assessed by CT or MRI scans and were performed at screening and every 8 weeks thereafter.</offsets></p><p><offsets xml_i="17221" xml_f="17455" txt_i="8846" txt_f="9080">Safety was assessed in all patients who received at least one dose of study drug. AEs and laboratory evaluations were monitored and graded according to the National Cancer Institute's Common Terminology Criteria for AEs, version 3.0 (</offsets><xref ref-type="bibr" rid="bib15"><offsets xml_i="17489" xml_f="17520" txt_i="9080" txt_f="9111">National Cancer Institute, 2006</offsets></xref><offsets xml_i="17527" xml_f="17654" txt_i="9111" txt_f="9238">). Vital signs were measured, physical examinations were performed and all concomitant medications and therapies were recorded.</offsets></p></sec><sec><title><offsets xml_i="17676" xml_f="17684" txt_i="9240" txt_f="9248">Analysis</offsets></title><p><offsets xml_i="17695" xml_f="17921" txt_i="9249" txt_f="9475">The Kaplan–Meier method was used to estimate median PFS for patients intolerant to previous VEGFr-TKI therapy in each treatment arm and the Cox proportional hazard model was used to calculate the HR of treatment effect on PFS.</offsets></p></sec><sec><title><offsets xml_i="17943" xml_f="17958" txt_i="9477" txt_f="9492">Ethical conduct</offsets></title><p><offsets xml_i="17969" xml_f="18265" txt_i="9493" txt_f="9789">RECORD-1 was conducted according to the ethical principles of the Declaration of Helsinki. The study protocol was reviewed by the independent ethics committee or institutional review board for each centre. Each patient provided written informed consent before screening procedures were initiated.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="18312" xml_f="18319" txt_i="9792" txt_f="9799">Results</offsets></title><p><offsets xml_i="18330" xml_f="18383" txt_i="9800" txt_f="9853">In the overall RECORD-1 population, 14% of patients (</offsets><italic><offsets xml_i="18391" xml_f="18392" txt_i="9853" txt_f="9854">n</offsets></italic><offsets xml_i="18401" xml_f="18968" txt_i="9854" txt_f="10421">=58) discontinued previous VEGFr-TKI therapy because of unacceptable toxicity. Among the subgroup of 58 patients who were intolerant to previous VEGFr-TKI therapy, 45 patients and 13 patients were randomly assigned to everolimus and placebo, respectively. Baseline characteristics in this subgroup of patients were generally similar to those of the overall study population; however, some differences between placebo-treated patients who were VEGFr-TKI-intolerant and all placebo-treated patients were noted (e.g., younger median age and higher percentage of women) (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="19002" xml_f="19009" txt_i="10421" txt_f="10428">Table 1</offsets></xref><offsets xml_i="19016" xml_f="19377" txt_i="10428" txt_f="10789">). When stratified by previous VEGFr-TKI therapy, of the 45 patients who received everolimus, 21 were intolerant to previous sunitinib, 19 were intolerant to previous sorafenib and 5 were intolerant to previous sunitinib and sorafenib. Of the 13 patients who received placebo, 5 were intolerant to previous sunitinib and 8 were intolerant to previous sorafenib.</offsets></p><p><offsets xml_i="19384" xml_f="19657" txt_i="10790" txt_f="11063">Among patients who were intolerant to previous VEGFr-TKI therapy and subsequently received everolimus or placebo, 42.2% and 84.6%, respectively, discontinued treatment because of disease progression, whereas 13% and 0%, respectively, discontinued treatment because of AEs (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="19691" xml_f="19698" txt_i="11063" txt_f="11070">Table 2</offsets></xref><offsets xml_i="19705" xml_f="19962" txt_i="11070" txt_f="11327">). AEs that led to discontinuation of everolimus treatment were asthenia, increased blood creatinine, dehydration, dyspnoea, increased gamma-glutamyltransferase, general physical health deterioration, pathological fracture, pleural effusion and pneumonitis.</offsets></p><p><offsets xml_i="19969" xml_f="20145" txt_i="11328" txt_f="11504">As was observed in the overall RECORD-1 population, everolimus significantly prolonged PFS compared with placebo in patients who were intolerant to previous VEGFr-TKI therapy (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="20177" xml_f="20185" txt_i="11504" txt_f="11512">Figure 1</offsets></xref><offsets xml_i="20192" xml_f="20419" txt_i="11512" txt_f="11739">). Median PFS was 5.4 months (95% CI: 3.8–5.9) with everolimus and 1.9 months (95% CI: 1.8–3.7) with placebo. Risk of disease progression was decreased by 68% with everolimus compared with placebo (HR: 0.32; 95% CI: 0.13–0.77; </offsets><italic><offsets xml_i="20427" xml_f="20428" txt_i="11739" txt_f="11740">P</offsets></italic><offsets xml_i="20437" xml_f="20445" txt_i="11740" txt_f="11748">=0.004).</offsets></p><p><offsets xml_i="20452" xml_f="20589" txt_i="11749" txt_f="11886">PFS benefit of everolimus compared with placebo was similar for patients who were intolerant to previous sunitinib or sorafenib therapy (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="20623" xml_f="20630" txt_i="11886" txt_f="11893">Table 3</offsets></xref><offsets xml_i="20637" xml_f="20852" txt_i="11893" txt_f="12108">). Among patients who were intolerant to previous sunitinib therapy, median PFS was 5.1 months (95% CI: 3.7–not available) with everolimus and 2.8 months (95% CI: 1.9–3.7) with placebo (HR: 0.28; 95% CI: 0.07–1.18; </offsets><italic><offsets xml_i="20860" xml_f="20861" txt_i="12108" txt_f="12109">P</offsets></italic><offsets xml_i="20870" xml_f="21091" txt_i="12109" txt_f="12330">=0.033). Among patients who were intolerant to previous sorafenib therapy, median PFS was 5.6 months (95% CI: 3.8–not available) with everolimus and 1.9 months (95% CI: 1.7–3.5) with placebo (HR: 0.29; 95% CI: 0.09–0.91; </offsets><italic><offsets xml_i="21099" xml_f="21100" txt_i="12330" txt_f="12331">P</offsets></italic><offsets xml_i="21109" xml_f="21117" txt_i="12331" txt_f="12339">=0.012).</offsets></p><p><offsets xml_i="21124" xml_f="21358" txt_i="12340" txt_f="12574">Everolimus was generally well tolerated in patients who were intolerant to previous VEGFr-TKI therapy, with low rates of grade 3 and grade 4 AEs, and the safety profile was similar to that observed in the overall RECORD-1 population (</offsets><xref rid="tbl4" ref-type="table"><offsets xml_i="21392" xml_f="21399" txt_i="12574" txt_f="12581">Table 4</offsets></xref><offsets xml_i="21406" xml_f="21766" txt_i="12581" txt_f="12941">). In the everolimus cohort of patients intolerant to previous VEGFr-TKI therapy, the most common AEs (all grade and grade ⩾3 incidence, respectively) were stomatitis (49% and 4%), fatigue (38% and 7%) and infections (33% and 16%), and the most commonly reported grade ⩾3 laboratory abnormalities were hyperglycaemia (20%), lymphopenia (20%) and anaemia (15%).</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="21810" xml_f="21820" txt_i="12943" txt_f="12953">Discussion</offsets></title><p><offsets xml_i="21831" xml_f="21970" txt_i="12954" txt_f="13093">Targeted therapies in mRCC are rarely curative, and patients often rely on multiple lines of therapy to derive sustained clinical benefit (</offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="22004" xml_f="22027" txt_i="13093" txt_f="13116">Oudard and Elaidi, 2012</offsets></xref><offsets xml_i="22034" xml_f="22653" txt_i="13116" txt_f="13735">). In patients with mRCC who are intolerant to first-line VEGF-targeted therapy and must discontinue treatment before disease progression, tolerability of subsequent therapy is of particular importance. Patients who require dose reductions/interruptions or cessation of treatment to manage toxicity associated with VEGF-targeted therapy may experience reduced efficacy of that agent. A recent pharmacokinetic/pharmacodynamic meta-analysis of sunitinib-treated patients with various types of cancer, including mRCC, demonstrated a positive relationship between drug exposure and time to progression or overall survival (</offsets><xref ref-type="bibr" rid="bib10"><offsets xml_i="22687" xml_f="22692" txt_i="13735" txt_f="13740">Houk </offsets><italic><offsets xml_i="22700" xml_f="22705" txt_i="13740" txt_f="13745">et al</offsets></italic><offsets xml_i="22714" xml_f="22720" txt_i="13745" txt_f="13751">, 2010</offsets></xref><offsets xml_i="22727" xml_f="22886" txt_i="13751" txt_f="13910">). However, increased sunitinib exposure was also associated with increased incidence of class-effect toxicities such as hypertension, neutropenia and fatigue.</offsets></p><p><offsets xml_i="22893" xml_f="23208" txt_i="13911" txt_f="14226">In previous studies of sequential administration of VEGF-targeted agents, overlapping toxicity profiles of these agents have resulted in high incidences of certain treatment-related AEs, such as hypertension, skin toxicities, fatigue and gastrointestinal toxicities, some of which have required dose modifications (</offsets><xref ref-type="bibr" rid="bib22"><offsets xml_i="23242" xml_f="23247" txt_i="14226" txt_f="14231">Rini </offsets><italic><offsets xml_i="23255" xml_f="23260" txt_i="14231" txt_f="14236">et al</offsets></italic><offsets xml_i="23269" xml_f="23275" txt_i="14236" txt_f="14242">, 2008</offsets></xref><offsets xml_i="23282" xml_f="23284" txt_i="14242" txt_f="14244">, </offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="23318" xml_f="23322" txt_i="14244" txt_f="14248">2011</offsets></xref><offsets xml_i="23329" xml_f="23331" txt_i="14248" txt_f="14250">; </offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="23364" xml_f="23375" txt_i="14250" txt_f="14261">Di Lorenzo </offsets><italic><offsets xml_i="23383" xml_f="23388" txt_i="14261" txt_f="14266">et al</offsets></italic><offsets xml_i="23397" xml_f="23403" txt_i="14266" txt_f="14272">, 2009</offsets></xref><offsets xml_i="23410" xml_f="23412" txt_i="14272" txt_f="14274">; </offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="23445" xml_f="23452" txt_i="14274" txt_f="14281">Garcia </offsets><italic><offsets xml_i="23460" xml_f="23465" txt_i="14281" txt_f="14286">et al</offsets></italic><offsets xml_i="23474" xml_f="23480" txt_i="14286" txt_f="14292">, 2010</offsets></xref><offsets xml_i="23487" xml_f="23561" txt_i="14292" txt_f="14366">). The AXIS phase-III trial evaluated the safety and efficacy of axitinib </offsets><italic><offsets xml_i="23569" xml_f="23571" txt_i="14366" txt_f="14368">vs</offsets></italic><offsets xml_i="23580" xml_f="23809" txt_i="14368" txt_f="14597"> sorafenib in patients with mRCC who had failed first-line treatment with a sunitinib-, bevacizumab-, temsirolimus- or cytokine-based regimen; 62% of patients received first-line VEGF-targeted therapy (sunitinib or bevacizumab) (</offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="23843" xml_f="23848" txt_i="14597" txt_f="14602">Rini </offsets><italic><offsets xml_i="23856" xml_f="23861" txt_i="14602" txt_f="14607">et al</offsets></italic><offsets xml_i="23870" xml_f="23876" txt_i="14607" txt_f="14613">, 2011</offsets></xref><offsets xml_i="23883" xml_f="24244" txt_i="14613" txt_f="14974">). In the overall AXIS population, class-effect AEs reported in the axitinib and sorafenib arms included diarrhoea (55% and 53%, respectively), hypertension (40% and 29%, respectively), fatigue (39% and 32%, respectively), palmar-plantar erythrodysaesthesia (27% and 51%, respectively), rash (13% and 32%, respectively) and alopecia (4% and 32%, respectively) (</offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="24278" xml_f="24283" txt_i="14974" txt_f="14979">Rini </offsets><italic><offsets xml_i="24291" xml_f="24296" txt_i="14979" txt_f="14984">et al</offsets></italic><offsets xml_i="24305" xml_f="24311" txt_i="14984" txt_f="14990">, 2011</offsets></xref><offsets xml_i="24318" xml_f="24528" txt_i="14990" txt_f="15200">). One or more dose reduction was reported in 31% and 52% of patients in the axitinib and sorafenib arms, respectively, and 77% and 80% of patients in each arm, respectively, had one or more dose interruption (</offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="24562" xml_f="24567" txt_i="15200" txt_f="15205">Rini </offsets><italic><offsets xml_i="24575" xml_f="24580" txt_i="15205" txt_f="15210">et al</offsets></italic><offsets xml_i="24589" xml_f="24595" txt_i="15210" txt_f="15216">, 2011</offsets></xref><offsets xml_i="24602" xml_f="24713" txt_i="15216" txt_f="15327">). Safety data for the subgroup of patients who failed previous VEGFr-TKI therapy (54%) has yet to be reported.</offsets></p><p><offsets xml_i="24720" xml_f="24810" txt_i="15328" txt_f="15418">The safety profile of mTOR inhibitors generally does not overlap with that of VEGFr-TKIs (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="24843" xml_f="24852" txt_i="15418" txt_f="15427">Escudier </offsets><italic><offsets xml_i="24860" xml_f="24865" txt_i="15427" txt_f="15432">et al</offsets></italic><offsets xml_i="24874" xml_f="24880" txt_i="15432" txt_f="15438">, 2007</offsets></xref><offsets xml_i="24887" xml_f="24889" txt_i="15438" txt_f="15440">; </offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="24923" xml_f="24930" txt_i="15440" txt_f="15447">Motzer </offsets><italic><offsets xml_i="24938" xml_f="24943" txt_i="15447" txt_f="15452">et al</offsets></italic><offsets xml_i="24952" xml_f="24958" txt_i="15452" txt_f="15458">, 2007</offsets></xref><offsets xml_i="24965" xml_f="24967" txt_i="15458" txt_f="15460">, </offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="25001" xml_f="25005" txt_i="15460" txt_f="15464">2010</offsets></xref><offsets xml_i="25012" xml_f="25391" txt_i="15464" txt_f="15843">), thus, patients who experience intolerance to VEGFr-TKI therapy may benefit from switching to an mTOR inhibitor. Most common grade ⩾3 AEs with everolimus in the overall RECORD-1 population were infections (10%), dyspnoea (7%), fatigue (5%) and stomatitis (∼5%), and most common grade ⩾3 laboratory abnormalities were lymphopenia (18%), hyperglycaemia (∼16%) and anaemia (13%) (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="25425" xml_f="25432" txt_i="15843" txt_f="15850">Motzer </offsets><italic><offsets xml_i="25440" xml_f="25445" txt_i="15850" txt_f="15855">et al</offsets></italic><offsets xml_i="25454" xml_f="25460" txt_i="15855" txt_f="15861">, 2010</offsets></xref><offsets xml_i="25467" xml_f="25673" txt_i="15861" txt_f="16067">). Noninfectious pneumonitis, a class effect of mTOR inhibitors, was reported in 13.5% of patients in the everolimus group of the RECORD-1 study (grade 1, 3.3% grade 2, 6.6% grade 3, 3.6% and grade 4, 0%) (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="25707" xml_f="25714" txt_i="16067" txt_f="16074">Motzer </offsets><italic><offsets xml_i="25722" xml_f="25727" txt_i="16074" txt_f="16079">et al</offsets></italic><offsets xml_i="25736" xml_f="25742" txt_i="16079" txt_f="16085">, 2010</offsets></xref><offsets xml_i="25749" xml_f="25751" txt_i="16085" txt_f="16087">; </offsets><xref ref-type="bibr" rid="bib25"><offsets xml_i="25785" xml_f="25791" txt_i="16087" txt_f="16093">White </offsets><italic><offsets xml_i="25799" xml_f="25804" txt_i="16093" txt_f="16098">et al</offsets></italic><offsets xml_i="25813" xml_f="25819" txt_i="16098" txt_f="16104">, 2010</offsets></xref><offsets xml_i="25826" xml_f="25828" txt_i="16104" txt_f="16106">; </offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="25862" xml_f="25868" txt_i="16106" txt_f="16112">Porta </offsets><italic><offsets xml_i="25876" xml_f="25881" txt_i="16112" txt_f="16117">et al</offsets></italic><offsets xml_i="25890" xml_f="25897" txt_i="16117" txt_f="16124">, 2011a</offsets></xref><offsets xml_i="25904" xml_f="26115" txt_i="16124" txt_f="16335">). Cardiovascular toxicity (hypertension, reduced left ventricular ejection fraction, cardiac ischaemia and infarction) and hand-foot skin reaction are not commonly observed in patients treated with everolimus (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="26148" xml_f="26157" txt_i="16335" txt_f="16344">Escudier </offsets><italic><offsets xml_i="26165" xml_f="26170" txt_i="16344" txt_f="16349">et al</offsets></italic><offsets xml_i="26179" xml_f="26185" txt_i="16349" txt_f="16355">, 2007</offsets></xref><offsets xml_i="26192" xml_f="26194" txt_i="16355" txt_f="16357">; </offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="26228" xml_f="26235" txt_i="16357" txt_f="16364">Motzer </offsets><italic><offsets xml_i="26243" xml_f="26248" txt_i="16364" txt_f="16369">et al</offsets></italic><offsets xml_i="26257" xml_f="26263" txt_i="16369" txt_f="16375">, 2007</offsets></xref><offsets xml_i="26270" xml_f="26272" txt_i="16375" txt_f="16377">, </offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="26306" xml_f="26310" txt_i="16377" txt_f="16381">2010</offsets></xref><offsets xml_i="26317" xml_f="26319" txt_i="16381" txt_f="16383">).</offsets></p><p><offsets xml_i="26326" xml_f="26724" txt_i="16384" txt_f="16782">Results of this subgroup analysis of RECORD-1 demonstrate that everolimus is well tolerated and efficacious in patients who are intolerant to VEGFr-TKI therapy. VEGFr-TKI-intolerant patients, who may be at risk for experiencing treatment-related AEs, did not experience increased toxicity and, notably, did not experience increased rates of pneumonitis relative to the overall RECORD-1 population (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="26758" xml_f="26765" txt_i="16782" txt_f="16789">Motzer </offsets><italic><offsets xml_i="26773" xml_f="26778" txt_i="16789" txt_f="16794">et al</offsets></italic><offsets xml_i="26787" xml_f="26793" txt_i="16794" txt_f="16800">, 2010</offsets></xref><offsets xml_i="26800" xml_f="27203" txt_i="16800" txt_f="17203">). In this analysis, 13.3% of patients discontinued treatment with everolimus because of AEs, thus, the majority (86.7%) of VEGFr-TKI-intolerant patients did tolerate treatment with everolimus. Additionally, the median PFS of everolimus in patients who were intolerant to previous VEGFr-TKI therapy (5.4 months) was similar to the median PFS of all everolimus-treated patients in RECORD-1 (4.9 months) (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="27237" xml_f="27244" txt_i="17203" txt_f="17210">Motzer </offsets><italic><offsets xml_i="27252" xml_f="27257" txt_i="17210" txt_f="17215">et al</offsets></italic><offsets xml_i="27266" xml_f="27272" txt_i="17215" txt_f="17221">, 2010</offsets></xref><offsets xml_i="27279" xml_f="27281" txt_i="17221" txt_f="17223">).</offsets></p><p><offsets xml_i="27288" xml_f="27786" txt_i="17224" txt_f="17722">The retrospective nature of this analysis, small sample size, and lack of patient stratification within the subgroup suggest use of caution when interpreting these results. Furthermore, this analysis was not powered or designed to enable statistical comparison of efficacy or safety profiles between patients intolerant to VEGFr-TKI therapy and the overall RECORD-1 population. Further studies of everolimus in patients intolerant to VEGF-targeted therapy are warranted to confirm our observations.</offsets></p><p><offsets xml_i="27793" xml_f="27998" txt_i="17723" txt_f="17928">Recent evidence has indicated that sequential treatment with a VEGFr-TKI and an mTOR inhibitor may permit eventual rechallenge with a third-line VEGFr-TKI. A subset of RECORD-1 patients from French sites (</offsets><italic><offsets xml_i="28006" xml_f="28007" txt_i="17928" txt_f="17929">n</offsets></italic><offsets xml_i="28016" xml_f="28204" txt_i="17929" txt_f="18117">=36) demonstrated a median PFS of 5.3 months for sorafenib, 8 months for sunitinib and 12 months for dovitinib (TKI258) after disease progression on at least one VEGFr-TKI and everolimus (</offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="28237" xml_f="28245" txt_i="18117" txt_f="18125">Blesius </offsets><italic><offsets xml_i="28253" xml_f="28258" txt_i="18125" txt_f="18130">et al</offsets></italic><offsets xml_i="28267" xml_f="28273" txt_i="18130" txt_f="18136">, 2010</offsets></xref><offsets xml_i="28280" xml_f="28346" txt_i="18136" txt_f="18202">). Another subset of RECORD-1 patients from a German institution (</offsets><italic><offsets xml_i="28354" xml_f="28355" txt_i="18202" txt_f="18203">n</offsets></italic><offsets xml_i="28364" xml_f="28528" txt_i="18203" txt_f="18367">=39) achieved a median PFS of 5.1 months after receiving sorafenib, sunitinib or dovitinib following previous treatment with at least one VEGFr-TKI and everolimus (</offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="28561" xml_f="28571" txt_i="18367" txt_f="18377">Gruenwald </offsets><italic><offsets xml_i="28579" xml_f="28584" txt_i="18377" txt_f="18382">et al</offsets></italic><offsets xml_i="28593" xml_f="28599" txt_i="18382" txt_f="18388">, 2010</offsets></xref><offsets xml_i="28606" xml_f="28643" txt_i="18388" txt_f="18425">). In a retrospective Italian study (</offsets><italic><offsets xml_i="28651" xml_f="28652" txt_i="18425" txt_f="18426">n</offsets></italic><offsets xml_i="28661" xml_f="28894" txt_i="18426" txt_f="18659">=34), third-line sorafenib after sequential therapy with sunitinib followed by everolimus or temsirolimus was associated with a median PFS of 4 months and a median overall survival of 7 months from initiation of sorafenib treatment (</offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="28927" xml_f="28938" txt_i="18659" txt_f="18670">Di Lorenzo </offsets><italic><offsets xml_i="28946" xml_f="28951" txt_i="18670" txt_f="18675">et al</offsets></italic><offsets xml_i="28960" xml_f="28966" txt_i="18675" txt_f="18681">, 2010</offsets></xref><offsets xml_i="28973" xml_f="29240" txt_i="18681" txt_f="18948">). A phase-III study designed to compare the safety and efficacy of dovitinib and sorafenib in patients with mRCC whose disease has progressed on one previous VEGFr-TKI and one previous mTOR inhibitor is currently ongoing (ClinicalTrials.gov identifier: NCT01223027).</offsets></p><p><offsets xml_i="29247" xml_f="29777" txt_i="18949" txt_f="19479">In conclusion, appropriate selection of second-line therapy to maximise clinical benefit and minimise the occurrence of treatment-related AEs for patients who are intolerant of initial VEGF-targeted therapy is a key clinical issue. Results of this subgroup analysis of the phase-III RECORD-1 study demonstrate that everolimus can be safely given to patients with a previous intolerance to VEGFr-TKI therapy. These results further support everolimus as the treatment of choice in patients who have failed initial VEGFr-TKI therapy.</offsets></p></sec></body><back><ack><p>Editorial assistance was provided by ApotheCom, Yardley, PA, USA, and funded by Novartis Pharmaceuticals Corporation.</p></ack><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blesius</surname><given-names>A</given-names></name><name><surname>Beuselinck</surname><given-names>B</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name></person-group><year>2010</year><article-title>Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial</article-title><source>Ann Oncol</source><volume>21</volume><supplement>(Suppl 8</supplement><fpage>viii284</fpage>(Abstract 908P)</mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Duh</surname><given-names>MS</given-names></name><name><surname>Clement</surname><given-names>J</given-names></name><name><surname>Brick</surname><given-names>AJ</given-names></name><name><surname>Rogers</surname><given-names>MJ</given-names></name><name><surname>Kwabi</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Percy</surname><given-names>AG</given-names></name><name><surname>Antras</surname><given-names>L</given-names></name><name><surname>Jayawant</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>ST</given-names></name><name><surname>Luka</surname><given-names>A</given-names></name><name><surname>Neary</surname><given-names>MP</given-names></name><name><surname>McDermott</surname><given-names>D</given-names></name><name><surname>Oh</surname><given-names>WK</given-names></name></person-group><year>2010</year><article-title>Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review</article-title><source>BJU Int</source><volume>105</volume><fpage>1247</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">19863525</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Reijke</surname><given-names>TM</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>van Poppel</surname><given-names>H</given-names></name><name><surname>Marreaud</surname><given-names>S</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>EORTC-GU group expert opinion on metastatic renal cell cancer</article-title><source>Eur J Cancer</source><volume>45</volume><fpage>765</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">19157861</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>G</given-names></name><name><surname>Carteni</surname><given-names>G</given-names></name><name><surname>Autorino</surname><given-names>R</given-names></name><name><surname>Bruni</surname><given-names>G</given-names></name><name><surname>Tudini</surname><given-names>M</given-names></name><name><surname>Rizzo</surname><given-names>M</given-names></name><name><surname>Aieta</surname><given-names>M</given-names></name><name><surname>Gonnella</surname><given-names>A</given-names></name><name><surname>Rescigno</surname><given-names>P</given-names></name><name><surname>Perdona</surname><given-names>S</given-names></name><name><surname>Giannarini</surname><given-names>G</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Longo</surname><given-names>N</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Imbimbo</surname><given-names>C</given-names></name><name><surname>De Laurentiis</surname><given-names>M</given-names></name><name><surname>Mirone</surname><given-names>V</given-names></name><name><surname>Ficorella</surname><given-names>C</given-names></name><name><surname>De Placido</surname><given-names>S</given-names></name></person-group><year>2009</year><article-title>Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>4469</fpage><lpage>4474</lpage><pub-id pub-id-type="pmid">19652053</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>G</given-names></name><name><surname>Buonerba</surname><given-names>C</given-names></name><name><surname>Federico</surname><given-names>P</given-names></name><name><surname>Rescigno</surname><given-names>P</given-names></name><name><surname>Milella</surname><given-names>M</given-names></name><name><surname>Ortega</surname><given-names>C</given-names></name><name><surname>Aieta</surname><given-names>M</given-names></name><name><surname>D'Aniello</surname><given-names>C</given-names></name><name><surname>Longo</surname><given-names>N</given-names></name><name><surname>Felici</surname><given-names>A</given-names></name><name><surname>Ruggeiri</surname><given-names>EM</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Imbimbo</surname><given-names>C</given-names></name><name><surname>Aglietta</surname><given-names>M</given-names></name><name><surname>De Placido</surname><given-names>S</given-names></name><name><surname>Mirone</surname><given-names>V</given-names></name></person-group><year>2010</year><article-title>Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma</article-title><source>Eur Urol</source><volume>58</volume><fpage>906</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">20884115</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Siebels</surname><given-names>M</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Solska</surname><given-names>E</given-names></name><name><surname>Desai</surname><given-names>AA</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Demkow</surname><given-names>T</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><collab>for the TARGET Study Group</collab></person-group><year>2007</year><article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title><source>N Engl J Med</source><volume>356</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">17215530</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Kataja</surname><given-names>V</given-names></name></person-group><year>2010</year><article-title>Renal cell carcinoma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><volume>21</volume><supplement>(Suppl 5</supplement><fpage>v137</fpage><lpage>v139</lpage><pub-id pub-id-type="pmid">20555064</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JA</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Elson</surname><given-names>P</given-names></name><name><surname>Cowey</surname><given-names>CL</given-names></name><name><surname>Gilligan</surname><given-names>T</given-names></name><name><surname>Nemec</surname><given-names>C</given-names></name><name><surname>Dreicer</surname><given-names>R</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name></person-group><year>2010</year><article-title>Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab</article-title><source>Cancer</source><volume>116</volume><fpage>5383</fpage><lpage>5390</lpage><pub-id pub-id-type="pmid">20806321</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Gruenwald</surname><given-names>V</given-names></name><name><surname>Seidel</surname><given-names>C</given-names></name><name><surname>Fenner</surname><given-names>M</given-names></name><name><surname>Heuser</surname><given-names>M</given-names></name><name><surname>Ganser</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC)</article-title>Presented at the 2010 ASCO Genitourinary Cancers Symposium, 5–7 March 2010, San Francisco, CA, USA (Abstract 414)</mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houk</surname><given-names>BE</given-names></name><name><surname>Bello</surname><given-names>CL</given-names></name><name><surname>Poland</surname><given-names>B</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><year>2010</year><article-title>Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis</article-title><source>Cancer Chemother Pharmacol</source><volume>66</volume><fpage>357</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">19967539</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungberg</surname><given-names>B</given-names></name><name><surname>Cowan</surname><given-names>NC</given-names></name><name><surname>Hanbury</surname><given-names>DC</given-names></name><name><surname>Hora</surname><given-names>M</given-names></name><name><surname>Kuczyk</surname><given-names>MA</given-names></name><name><surname>Merseburger</surname><given-names>AS</given-names></name><name><surname>Patard</surname><given-names>JJ</given-names></name><name><surname>Mulders</surname><given-names>PF</given-names></name><name><surname>Sinescu</surname><given-names>IC</given-names></name></person-group><year>2010</year><article-title>EAU guidelines on renal cell carcinoma: the 2010 update</article-title><source>Eur Urol</source><volume>58</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">20633979</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Grunwald</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Hollaender</surname><given-names>N</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors</article-title><source>Cancer</source><volume>116</volume><fpage>4256</fpage><lpage>4265</lpage><pub-id pub-id-type="pmid">20549832</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Grunwald</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Hollaender</surname><given-names>N</given-names></name><name><surname>Urbanowitz</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>WJ</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Lebwohl</surname><given-names>D</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><collab>for the RECORD-1 Study Group</collab></person-group><year>2008</year><article-title>Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</article-title><source>Lancet</source><volume>372</volume><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">18653228</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rixe</surname><given-names>O</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Bycott</surname><given-names>PW</given-names></name><name><surname>Baum</surname><given-names>CM</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><year>2007</year><article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title><source>N Engl J Med</source><volume>356</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">17215529</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>National Cancer Institute</collab></person-group><year>2006</year><article-title>Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute Web site</article-title><x>
.
</x><ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/reporting/ctc_v30.html">http://ctep.cancer.gov/reporting/ctc_v30.html</ext-link><x>
</x>accessed on 24 October 2011</mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group><year>2012</year><article-title>NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. V.1.2012</article-title>National Comprehensive Cancer Network Web site.<x>
</x><ext-link ext-link-type="uri" xlink:href="http://www.nccn.org">http://www.nccn.org</ext-link><x>
</x>accessed on 2 February 2012</mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Elaidi</surname><given-names>RT</given-names></name></person-group><year>2012</year><article-title>Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit</article-title><source>Cancer Treat Rev</source><x>
,
</x><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ctrv.2011.12.009">http://dx.doi.org/10.1016/j.ctrv.2011.12.009</ext-link></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Ostanto</surname><given-names>S</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Climent</surname><given-names>MA</given-names></name><name><surname>Vaishampayan</surname><given-names>U</given-names></name><name><surname>White</surname><given-names>DA</given-names></name><name><surname>Creel</surname><given-names>P</given-names></name><name><surname>Dickow</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>P</given-names></name><name><surname>Gornell</surname><given-names>SS</given-names></name><name><surname>Meloni</surname><given-names>F</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><year>2011b</year><article-title>Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma</article-title><source>Eur J Cancer</source><volume>47</volume><fpage>1287</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">21481584</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Paglino</surname><given-names>C</given-names></name><name><surname>Imarisio</surname><given-names>I</given-names></name><name><surname>Canipari</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Neary</surname><given-names>M</given-names></name><name><surname>Duh</surname><given-names>MS</given-names></name></person-group><year>2011a</year><article-title>Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy</article-title><source>BMC Cancer</source><volume>11</volume><fpage>105</fpage><pub-id pub-id-type="pmid">21435216</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name></person-group><year>2011</year><article-title>Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies</article-title><source>Oncologist</source><volume>16</volume><supplement>(Suppl 2</supplement><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">21346038</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Kaprin</surname><given-names>A</given-names></name><name><surname>Szcylik</surname><given-names>C</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Gorbunova</surname><given-names>VA</given-names></name><name><surname>Gore</surname><given-names>ME</given-names></name><name><surname>Rusakov</surname><given-names>IG</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Ou</surname><given-names>YC</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Uemura</surname><given-names>H</given-names></name><name><surname>Tarazi</surname><given-names>J</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Rosbrook</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><year>2011</year><article-title>Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial</article-title><source>Lancet</source><volume>378</volume><fpage>1931</fpage><lpage>1939</lpage><pub-id pub-id-type="pmid">22056247</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Margolin</surname><given-names>K</given-names></name><name><surname>Harmon</surname><given-names>CS</given-names></name><name><surname>DePrimo</surname><given-names>SE</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>George</surname><given-names>DJ</given-names></name></person-group><year>2008</year><article-title>Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><volume>26</volume><fpage>3743</fpage><lpage>3748</lpage><pub-id pub-id-type="pmid">18669461</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>CN</given-names></name><name><surname>Davis</surname><given-names>ID</given-names></name><name><surname>Mardiak</surname><given-names>J</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Wagstaff</surname><given-names>J</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Salman</surname><given-names>P</given-names></name><name><surname>Gladkov</surname><given-names>OA</given-names></name><name><surname>Kavina</surname><given-names>A</given-names></name><name><surname>Zarba</surname><given-names>JJ</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Pandite</surname><given-names>L</given-names></name><name><surname>Roychowdhury</surname><given-names>DF</given-names></name><name><surname>Hawkins</surname><given-names>RE</given-names></name></person-group><year>2010</year><article-title>Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">20100962</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><year>2000</year><article-title>New guidelines to evaluate the response to treatment in solid tumors</article-title><source>J Natl Cancer Inst</source><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">10655437</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>DA</given-names></name><name><surname>Camus</surname><given-names>P</given-names></name><name><surname>Endo</surname><given-names>M</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Akaza</surname><given-names>H</given-names></name><name><surname>Uemura</surname><given-names>H</given-names></name><name><surname>Kpamegan</surname><given-names>E</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Robson</surname><given-names>M</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><year>2010</year><article-title>Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma</article-title><source>Am J Respir Crit Care Med</source><volume>182</volume><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">20194812</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Kaplan–Meier estimates of PFS by treatment group in the patients intolerant of previous VEGFr-TKI therapy (<bold>A</bold>) and the overall RECORD-1 population (<bold>B</bold>) (<xref ref-type="bibr" rid="bib12">Motzer <italic>et al</italic>, 2010</xref>). <xref ref-type="fig" rid="fig1">Figure 1B</xref> was reprinted from <xref ref-type="bibr" rid="bib12">Motzer <italic>et al</italic>, 2010</xref>, copyright (2010), with permission from John Wiley &amp; Sons (Hoboken, NJ, USA). Abbreviations: PFS=progression-free survival; VEGFr-TKI=vascular endothelial growth factor receptor-tyrosine kinase inhibitor.</p></caption><graphic xlink:href="bjc201289f1"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Patient demographics in the subgroup of patients who were intolerant of previous VEGFr-TKI therapy and all patients in the RECORD-1 trial</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="("></col><col align="char" char="("></col><col align="char" char="("></col><col align="char" char="("></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>VEGFr-TKI-intolerant patients</bold><hr></hr></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>All patients (<xref ref-type="bibr" rid="bib12">Motzer <italic>et al</italic>, 2010</xref>)</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="(" charoff="50"><bold>Everolimus+BSC</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Placebo+BSC</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Everolimus+BSC</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Placebo+BSC</bold></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="char" valign="top" char="(" charoff="50"><bold><italic>n</italic></bold>=<bold>45</bold></th><th align="char" valign="top" char="(" charoff="50"><bold><italic>n</italic></bold>=<bold>13</bold></th><th align="char" valign="top" char="(" charoff="50"><bold><italic>n</italic></bold>=<bold>277</bold></th><th align="char" valign="top" char="(" charoff="50"><bold><italic>n</italic></bold>=<bold>139</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age in years, median (range)</td><td align="char" valign="top" char="(" charoff="50">66 (44–81)</td><td align="char" valign="top" char="(" charoff="50">41 (29–74)</td><td align="char" valign="top" char="(" charoff="50">61 (27–85)</td><td align="char" valign="top" char="(" charoff="50">60 (29–79)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Sex, n (%)</italic></td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Men</td><td align="char" valign="top" char="(" charoff="50">28 (62)</td><td align="char" valign="top" char="(" charoff="50">5 (39)</td><td align="char" valign="top" char="(" charoff="50">216 (78)</td><td align="char" valign="top" char="(" charoff="50">106 (76)</td></tr><tr><td align="left" valign="top" charoff="50"> Women</td><td align="char" valign="top" char="(" charoff="50">17 (38)</td><td align="char" valign="top" char="(" charoff="50">8 (62)</td><td align="char" valign="top" char="(" charoff="50">61 (22)</td><td align="char" valign="top" char="(" charoff="50">33 (24)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>KPS score, n (%)</italic></td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> 100</td><td align="char" valign="top" char="(" charoff="50">10 (22)</td><td align="char" valign="top" char="(" charoff="50">1 (8)</td><td align="char" valign="top" char="(" charoff="50">78 (28)</td><td align="char" valign="top" char="(" charoff="50">41 (30)</td></tr><tr><td align="left" valign="top" charoff="50"> 90</td><td align="char" valign="top" char="(" charoff="50">16 (36)</td><td align="char" valign="top" char="(" charoff="50">6 (27)</td><td align="char" valign="top" char="(" charoff="50">98 (35)</td><td align="char" valign="top" char="(" charoff="50">53 (38)</td></tr><tr><td align="left" valign="top" charoff="50"> 80</td><td align="char" valign="top" char="(" charoff="50">18 (40)</td><td align="char" valign="top" char="(" charoff="50">5 (22)</td><td align="char" valign="top" char="(" charoff="50">72 (26)</td><td align="char" valign="top" char="(" charoff="50">30 (22)</td></tr><tr><td align="left" valign="top" charoff="50"> 70</td><td align="char" valign="top" char="(" charoff="50">1 (2)</td><td align="char" valign="top" char="(" charoff="50">1 (8)</td><td align="char" valign="top" char="(" charoff="50">28 (10)</td><td align="char" valign="top" char="(" charoff="50">15 (11)</td></tr><tr><td align="left" valign="top" charoff="50"> Missing</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">1 (&lt;1)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>MSKCC-risk group, n (%)</italic></td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Favourable</td><td align="char" valign="top" char="(" charoff="50">13 (29)</td><td align="char" valign="top" char="(" charoff="50">3 (23)</td><td align="char" valign="top" char="(" charoff="50">81 (29)</td><td align="char" valign="top" char="(" charoff="50">39 (28)</td></tr><tr><td align="left" valign="top" charoff="50"> Intermediate</td><td align="char" valign="top" char="(" charoff="50">30 (67)</td><td align="char" valign="top" char="(" charoff="50">8 (62)</td><td align="char" valign="top" char="(" charoff="50">156 (56)</td><td align="char" valign="top" char="(" charoff="50">79 (57)</td></tr><tr><td align="left" valign="top" charoff="50"> Poor</td><td align="char" valign="top" char="(" charoff="50">2 (4)</td><td align="char" valign="top" char="(" charoff="50">2 (15)</td><td align="char" valign="top" char="(" charoff="50">40 (14)</td><td align="char" valign="top" char="(" charoff="50">21 (15)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: BSC=best supportive care; KPS=Karnofsky performance status; MSKCC=Memorial Sloan–Kettering Cancer Center; VEGFr-TKI=vascular endothelial growth factor receptor-tyrosine kinase inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Rates and reasons for discontinuation of everolimus or placebo in patients who were intolerant of previous VEGFr-TKI therapy</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="("></col><col align="char" char="("></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Discontinuations, <italic>n</italic> (%)</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Everolimus+BSC <italic>n</italic></bold>=<bold>45</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Placebo+BSC <italic>n</italic></bold>=<bold>13</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50">30 (66.7)</td><td align="char" valign="top" char="(" charoff="50">12 (92.3)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Reason for discontinuation, n (%)</italic></td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Disease progression</td><td align="char" valign="top" char="(" charoff="50">19 (42.2)</td><td align="char" valign="top" char="(" charoff="50">11 (84.6)</td></tr><tr><td align="left" valign="top" charoff="50"> Adverse event</td><td align="char" valign="top" char="(" charoff="50">6 (13.3)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Consent withdrawn</td><td align="char" valign="top" char="(" charoff="50">3 (6.7)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Abnormal laboratory value</td><td align="char" valign="top" char="(" charoff="50">1 (2.2)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Lost to follow-up</td><td align="char" valign="top" char="(" charoff="50">1 (2.2)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Death</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">1 (7.7)</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: BSC=best supportive care; VEGFr-TKI=vascular endothelial growth factor receptor-tyrosine kinase inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>PFS in patients intolerant to previous sunitinib and/or sorafenib therapy</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>Intolerant to previous sunitinib<xref ref-type="fn" rid="t3-fn2">a</xref></bold><hr></hr></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Intolerant to previous sorafenib<xref ref-type="fn" rid="t3-fn3">b</xref></bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>Everolimus+BSC</bold></th><th align="center" valign="top" charoff="50"><bold>Placebo+BSC</bold></th><th align="center" valign="top" charoff="50"><bold>Everolimus+BSC</bold></th><th align="center" valign="top" charoff="50"><bold>Placebo+BSC</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Patients, <italic>n</italic></td><td align="center" valign="top" charoff="50">26<xref ref-type="fn" rid="t3-fn4">c</xref></td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">24<xref ref-type="fn" rid="t3-fn4">c</xref></td><td align="center" valign="top" charoff="50">8</td></tr><tr><td align="left" valign="top" charoff="50">PFS in months, median (95% CI)</td><td align="center" valign="top" charoff="50">5.1 (3.7–NA)</td><td align="center" valign="top" charoff="50">2.8 (1.9–3.7)</td><td align="center" valign="top" charoff="50">5.6 (3.8–NA)</td><td align="center" valign="top" charoff="50">1.9 (1.7–3.5)</td></tr><tr><td align="left" valign="top" charoff="50">Hazard ratio (95% CI)</td><td colspan="2" align="center" valign="top" charoff="50">0.28 (0.07–1.18), <italic>P</italic>=0.033</td><td colspan="2" align="center" valign="top" charoff="50">0.29 (0.09–0.91), <italic>P</italic>=0.012</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: BSC=best supportive care; CI=confidence interval; NA=not available; PFS=progression-free survival.</p></fn><fn id="t3-fn2"><label>a</label><p>Patients who had an adverse event (AE) as the primary reason for discontinuation of previous sunitinib. Patients may have also received previous sorafenib.</p></fn><fn id="t3-fn3"><label>b</label><p>Patients who had an AE as the primary reason for discontinuation of previous sorafenib. Patients may have also received previous sunitinib.</p></fn><fn id="t3-fn4"><label>c</label><p>Of the 45 VEGFr-TKI-intolerant patients randomly assigned to everolimus, 5 patients were intolerant to both previous sunitinib and sorafenib and were included in both previous treatment groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Commonly reported adverse events and laboratory abnormalities, irrespective of relation to treatment, in patients intolerant to previous VEGFr-TKI therapy and the overall RECORD-1 population</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="6" align="center" valign="top" charoff="50"><bold>Patients intolerant to previous VEGFr-TKI therapy</bold><hr></hr></th><th colspan="6" align="center" valign="top" charoff="50"><bold>All patients</bold>
<bold>(<xref ref-type="bibr" rid="bib12">Motzer <italic>et al</italic>, 2010</xref>)</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" charoff="50"><bold>Everolimus+BSC, <italic>n</italic></bold>=<bold>45</bold><hr></hr></th><th colspan="3" align="center" valign="top" charoff="50"><bold>Placebo+BSC, <italic>n</italic></bold>=<bold>13</bold><hr></hr></th><th colspan="3" align="center" valign="top" charoff="50"><bold>Everolimus+BSC, <italic>n</italic></bold>=<bold>274</bold><hr></hr></th><th colspan="3" align="center" valign="top" charoff="50"><bold>Placebo+BSC, <italic>n</italic></bold>=<bold>137</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th align="left" valign="top" charoff="50"><bold>All grade</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 3</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 4</bold></th><th align="left" valign="top" charoff="50"><bold>All grade</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 3</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 4</bold></th><th align="left" valign="top" charoff="50"><bold>All grade</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 3</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 4</bold></th><th align="left" valign="top" charoff="50"><bold>All grade</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 3</bold></th><th align="left" valign="top" charoff="50"><bold>Grade 4</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>Adverse event, %</italic></td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> Stomatitis<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="char" valign="top" char="." charoff="50">49</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">15</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">44</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">&lt;1</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Fatigue</td><td align="char" valign="top" char="." charoff="50">38</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">27</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">&lt;1</td></tr><tr><td align="left" valign="top" charoff="50"> Infections<xref ref-type="fn" rid="t4-fn3">b</xref></td><td align="char" valign="top" char="." charoff="50">33</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">37</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">18</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Diarrhoea</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">30</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Rash</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">29</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Nausea</td><td align="char" valign="top" char="." charoff="50">27</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">26</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Asthenia</td><td align="char" valign="top" char="." charoff="50">24</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">33</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">&lt;1</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Peripheral oedema</td><td align="char" valign="top" char="." charoff="50">24</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">15</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">25</td><td align="char" valign="top" char="." charoff="50">&lt;1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">&lt;1</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Mucosal inflammation</td><td align="char" valign="top" char="." charoff="50">16</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">19</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="13" align="left" valign="top" charoff="50"><italic>Laboratory abnormality, %</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Haemoglobin decreased</td><td align="char" valign="top" char="." charoff="50">96</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">92</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">92</td><td align="char" valign="top" char="." charoff="50">12</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">79</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">&lt;1</td></tr><tr><td align="left" valign="top" charoff="50"> Cholesterol increased</td><td align="char" valign="top" char="." charoff="50">78</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">38</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">77</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">35</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Triglycerides increased</td><td align="char" valign="top" char="." charoff="50">76</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">73</td><td align="char" valign="top" char="." charoff="50">&lt;1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">34</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Glucose increased</td><td align="char" valign="top" char="." charoff="50">64</td><td align="char" valign="top" char="." charoff="50">20</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">57</td><td align="char" valign="top" char="." charoff="50">15</td><td align="char" valign="top" char="." charoff="50">&lt;1</td><td align="char" valign="top" char="." charoff="50">25</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Lymphocytes decreased</td><td align="char" valign="top" char="." charoff="50">64</td><td align="char" valign="top" char="." charoff="50">18</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">51</td><td align="char" valign="top" char="." charoff="50">16</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">28</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Creatinine increased</td><td align="char" valign="top" char="." charoff="50">60</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">31</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">50</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">34</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Platelets decreased</td><td align="char" valign="top" char="." charoff="50">40</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">23</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">&lt;1</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: BSC=best supportive care; VEGFr-TKI=vascular endothelial growth factor receptor-tyrosine kinase inhibitor.</p></fn><fn id="t4-fn2"><label>a</label><p>Stomatitis (including aphthous stomatitis), mouth ulceration and tongue ulceration.</p></fn><fn id="t4-fn3"><label>b</label><p>All infections reported, including pneumonia, aspergillosis, candidiasis and sepsis.</p></fn></table-wrap-foot></table-wrap></floats-group></article>